There is widespread recognition that relief of post-operative pain is sub-optimal. In DepoDur^™ (previously known as DepoMorphine^™), our DepoFoam^™ sustained-release injectable technology maintains therapeutically effective levels of morphine for 48 hours (the period of peak post-operative pain) from a single epidural injection given before or during the procedure. Epidural analgesia has many theoretical advantages but is only used in about 50% of procedures today because of some practical issues. Conventional morphine is relatively short-acting so the epidural catheter has to be left in place. This impairs patient mobility and may cause complications such as infections and bleeding within the spinal column that could cause paralysis. DepoDur^™ eliminates the need for an indwelling catheter and infusion pumps.

Clinical trials in several different post-operative indications confirm that the product is safe and at least as effective as conventional morphine. DepoDur^™ was filed with the FDA in July 2003, approved in May 2004 and launched in the USA in December 2004. DepoDur^™ was filed in Europe in November 2003 and was approved by the MHRA in April 2006. DepoDur^™ was licensed to Endo Pharmaceuticals for North America at the end of 2002 and to Zeneus Pharma for Europe in 2004 . However following the 2005 acquisition of Zeneus by Cephalon SkyePharma has reacquired the rights in Europe.

	12/6/2004		Two Days of Post-Surgical Pain Relief Now Possible With Just One Shot

	"Postoperative pain management continues to be a significantly underserved area. DepoMorphine™ holds the promise of providing excellent pain relief without the burdens and risk associated with indwelling catheters. Anyone having a major operation will appreciate this advantage." Thomas Jefferson University - Eugene Viscusi, MD, Director, Acute Pain Management
	"DepoMorphine™ will substantially improve treatment of post-operative pain... DepoMorphine™ offers us the ability to give 2 to 3 days of highly reliable and effective pain relief in a much higher percentage of our patients." Stanford University - Edward Riley MD, Associate Professor
	"DepoMorphine™ may prove to be a revolutionary drug in postoperative pain management. The pain relief provided by DepoMorphine™ is far superior to that which can be achieved by PCA...up to at least 48 hours... The lack of need for catheter infusions may simplify pain management...especially in orthopedic patients where this may allow superior rehabilitation of patients." Duke University - Gavin Martin, MD, Assistant Clinical Professor

For further information on DepoDur^™, please visit www.depodur.com or email SkyePharma at ir@skyepharma.co.uk.